DNMT1 and cancer: Despite the fact that seven epidrugs such as DNMT (5-azacytidine) and HDAC inhibitors (SAHA) [133, 134] have been approved by government agencies (e.g. the FDA) in cancer therapies, lack of selectivity towards Plasmodium has been the major Achille’s heel in the development of antiplasmodial epidrugs.